CD70-targeted immunoPET Imaging of Malignant Cancers

Sponsor
RenJi Hospital
Study ID
NCT06852638
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • [18F]F-RESCA-RCCB6 — DRUG
    Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
  • [18F]F-RESCA-R8B4 — DRUG
    Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.
  • [68Ga]Ga-NOTA-R8B4 — DRUG
    Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.
  • [18F]F-RESCA-RD06 — DRUG
    Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]F-RESCA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RD06 injection.
  • [68Ga]Ga-NOTA-RD06 — DRUG
    Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RD06 injection.

Study Details

This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.

Key Dates

First listed
Feb 28, 2025
Start date
Dec 23, 2024
Status verified
May 2026
Primary completion
Dec 23, 2026
Completion
Dec 23, 2026

Study Design

Enrollment
300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: CD70-targeted immunoPET imaging
    Enrolled patients will undergo a CD70-targeted immunoPET/CT scanning.

Primary Outcome Measure

The uptake patterns of CD70-targeted tracers across different tumors [ Time Frame: One month after the injection of the tracers ]

Central Contacts

Find similar trials

Nationwide
Kidney cancer trialsOncology trialsUrology trials

Related Studies